Did retatrutide lose more lean mass than semaglutide or tirzepatide?

The published substudy compared retatrutide with placebo and dulaglutide 1.5 mg, not with semaglutide or tirzepatide. The authors reported that the lean-to-weight loss proportion resembled other obesity treatments. No head-to-head DXA comparison against semaglutide or tirzepatide appears in the sources reviewed here.

Was lean mass loss worse at 12 mg than at 8 mg?

The substudy cannot answer that. Total fat mass fell 26.1% in the pooled 8 mg group and 23.2% at 12 mg, and only 30 participants were assigned to 12 mg. With 103 people completing both scans across six groups, the arms are too small for a reliable dose comparison.

How is lean mass tracked during treatment?

DXA is the method the trials used. Research reviews also use CT or MRI when they want skeletal muscle specifically rather than the whole fat-free compartment. Strength and physical function tests measure something different from mass, and the two do not always move together.

Does gray-market retatrutide have the same effect on body composition?

There is no data on that. Every result described here came from Lilly-manufactured drug given under a monitored protocol. Products sold online are not verified for identity, purity or milligram content, so trial body composition findings do not transfer to them.

Is losing lean mass always harmful?

Not necessarily, and some decline is expected with any large calorie deficit. Fat-free mass includes water, organ tissue and connective tissue, not only muscle. One review still found skeletal muscle made up 92% to 97% of the fat-free mass lost during weight reduction, so the amount is worth watching.

Does Retatrutide Cause Muscle Loss? What the DXA Data Shows

The short answer: Retatrutide is investigational and not FDA approved, so every figure below comes from trial data. Only one retatrutide trial has published a DXA body-composition substudy, and it was the phase 2 type 2 diabetes trial, not the obesity trial. Fat mass fell far more than lean mass, and the authors reported that the lean-to-total loss ratio looked like other obesity treatments. No body-composition results have been published from the phase 3 TRIUMPH program.

What does the published retatrutide body composition data actually show?

One retatrutide trial measured body composition with dual-energy X-ray absorptiometry (DXA). It was a prespecified substudy of the phase 2 type 2 diabetes trial, NCT04867785. Coskun and colleagues published it in The Lancet Diabetes and Endocrinology in 2025.

The sample is small. 189 participants entered the substudy. Only 155 had a baseline DXA scan, and 103 completed treatment with both a baseline scan and a week 36 scan. Those 103 people were split across six treatment groups.

Total fat mass fell from baseline to week 36 by:

4.9% with retatrutide 0.5 mg
15.2% with retatrutide 4 mg (pooled)
26.1% with retatrutide 8 mg (pooled)
23.2% with retatrutide 12 mg
4.5% with placebo and 2.6% with dulaglutide 1.5 mg

The authors concluded that "the proportion of lean mass loss to weight loss was similar to other obesity treatments." They added that the result "could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss."

A 2026 systematic review in Diabetes, Obesity and Metabolism pooled the retatrutide arms from that substudy. It reported fat-free mass losses of 5.8 kg to 6.5 kg, depending on the dose.

Is lean mass loss the same thing as muscle loss?

No, and the difference matters when reading these numbers. DXA does not measure muscle directly. It measures a compartment called lean mass, or fat-free mass.

A 2026 review in the Journal of Cachexia, Sarcopenia and Muscle describes fat-free mass as a heterogeneous compartment. It contains skeletal muscle, organ mass such as brain, heart, liver and kidneys, and parts of connective tissue. Skeletal muscle makes up roughly 45% of fat-free mass in women and 49% in men.

So a DXA report showing a lean mass drop is not a muscle biopsy. Water, glycogen and organ tissue all sit inside that number.

That said, the nuance cuts both ways. The same review reports that skeletal muscle accounted for 92% to 97% of the fat-free mass lost during weight reduction in the studies it examined. Lean mass is a wider compartment than muscle, but muscle appears to supply most of what is lost.

How does retatrutide compare to diet, exercise, and surgery?

The Diabetes, Obesity and Metabolism review pooled 21 randomized trials with 1,334 participants. Every trial produced at least 10% weight loss and used DXA, CT or MRI. It reported the share of total weight loss that was fat-free mass:

Diet without exercise: 22.3%
Diet with exercise: 7.7%
Incretin-based drug therapies: 33.3%
Bariatric surgery: 34.2%

Absolute fat-free mass reductions were 1.80 kg for diet and exercise, 4.75 kg for incretin therapies versus placebo, and 9.14 kg for surgery.

This lines up with the older rule of thumb. An NIH-affiliated review of weight loss composition examined the "Quarter FFM Rule," the idea that about one quarter of weight lost is fat-free mass. It found the rule is "at best an approximation that has a limited mechanistic basis." One meta-analysis it cites reported 27% plus or minus 7% in men and 20% plus or minus 7% in women. The proportion shifts with energy intake, diet composition, sex and starting body fat.

Retatrutide sits inside that range. It looks worse than diet plus resistance exercise and about the same as surgery.

Does the glucagon receptor arm change the picture?

Retatrutide activates three receptors: GLP-1, GIP and glucagon. Our explainer on how the triple agonist works covers the pharmacology. The glucagon arm is the part that raises the muscle question, because glucagon drives both energy expenditure and amino acid catabolism.

The argument runs both ways. Higher energy expenditure could mean more of the deficit comes from fat. Amino acid catabolism could mean more protein breakdown. Published trials do not settle it.

What the data do show is a strong fat-depot signal. The MASLD substudy of the phase 2 obesity trial, reported by Sanyal and colleagues in Nature Medicine, measured abdominal fat by MRI. At 48 weeks, visceral adipose tissue fell 16.1% to 48.3% across doses, versus a 2.5% rise on placebo. Abdominal subcutaneous fat fell 13.2% to 43.5%, versus 0.1% on placebo. The same paper notes rising beta-hydroxybutyrate, consistent with more fat oxidation in the liver.

That substudy did not measure lean mass. In the sources reviewed here, no published retatrutide trial measured resting energy expenditure and lean mass in the same participants. So the claim that the glucagon arm protects muscle is untested, not proven.

What do the TRIUMPH phase 3 trials say about body composition?

Nothing yet, and possibly nothing later. The ClinicalTrials.gov record for TRIUMPH-1 lists 2,335 participants and 58 secondary outcome measures. Those cover weight loss thresholds up to 35%, waist circumference, BMI, blood pressure, lipids, HbA1c, quality of life, sleep apnea and knee osteoarthritis. None of them is lean mass, fat mass or DXA. Our retatrutide clinical trials tracker follows what each study reports.

This creates a real gap. TRIUMPH-1 produced far more weight loss than the phase 2 diabetes trial. Whether the fat-to-lean split holds at that magnitude is an open question, and the published substudy cannot answer it. Its 12 mg group had only 30 assigned participants, and fat mass reduction at 12 mg (23.2%) was slightly lower than the pooled 8 mg figure (26.1%). Read our guide to how much weight people lose on retatrutide for the weight results themselves.

Anyone who tells you retatrutide preserves muscle better than tirzepatide or semaglutide is going beyond the published record.

Does protein intake or resistance training protect lean mass?

The evidence here is real, but none of it comes from a retatrutide trial. It comes from general weight loss research.

The clearest signal is the exercise contrast in the pooled review: 22.3% of weight lost was fat-free mass with diet alone, versus 7.7% with diet plus exercise. That is roughly a threefold difference in partitioning.

On protein, the Journal of Cachexia, Sarcopenia and Muscle review cites a study where about 22 g of protein per meal (1.2 g per kg of body weight per day) combined with resistance exercise prevented lean mass loss. About 49 g per meal (2.4 g per kg per day) produced a gain of 1.2 kg plus or minus 1.0 kg.

A review of muscle loss after surgical and pharmacological weight loss is more cautious. Trials that preserved fat-free mass used more than 1.0 g per kg per day of protein. Resistance exercise reduced the decline in muscle strength after bariatric surgery, but participants still lost a significant amount of fat-free mass. The same pattern likely applies to drug-driven weight loss on GLP-1 based medications generally.

No retatrutide trial has randomized participants to a protein target or a resistance training program. Anyone extrapolating from the surgery and diet literature is making a reasonable guess, not citing retatrutide evidence.

The bottom line

Retatrutide causes lean mass loss, like every intervention that produces a large calorie deficit. The one published DXA substudy, in 103 people with type 2 diabetes who completed both scans, showed fat mass falling up to 26.1% and a lean-to-weight loss proportion the authors called similar to other obesity treatments. Pooled analysis puts incretin therapies at 33.3% of weight lost as fat-free mass, close to surgery at 34.2% and well above diet plus exercise at 7.7%. Lean mass is not the same measurement as muscle, though muscle supplies most of it. The glucagon receptor arm has a plausible effect on energy expenditure that no published retatrutide trial has measured alongside body composition. TRIUMPH lists no body-composition outcome at all, so the question at 28% weight loss stays open.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug that is not FDA approved. Trial body-composition results are reported for education and are not guidance for use, dosing, diet or exercise.